1. Scrip
  2. >>Business
  3. >>Earnings

Humira Market Erosion Is Continuing As Expected, AbbVie Says

 
• By Joseph Haas

With adalimumab biosimilar market share increasing in the US, AbbVie says revenue erosion is on its expected pace, driven mainly by discounts. Skyrizi, Rinvoq continue growth trajectories.

AbbVie building
AbbVie continues to manage Humira erosion despite rising biosimilar market share • Source: Alamy

AbbVie Inc. has enjoyed mainly plaudits for its handling of biosimilar competition to its top-seller, Humira (adalimumab), with its projections tracking close to reality since US biosimilars first entered the market in early 2023. But while the numbers for its blockbuster anti-TNF therapy remained solid in the first quarter sales and earnings reported on 26 April, analysts and investors are questioning how Humira will hold up with biosimilar adoption by US payers on the rise.

Humira brought in $2.27bn globally during the first quarter, down 35.9% year-over-year, including 39.9% US revenue erosion to $1.77bn. Ex-US, where biosimilar adalimumab has been on the market longer, revenue declined 15.8% to $499m. AbbVie has projected 36% revenue erosion for Humira for full-year 2024. Overall, AbbVie’s immunology segment saw a 3

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

More from Business

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.